Nanoformulation-assisted early diagnosis of prostate cancer: Advances and perspectives

纳米制剂辅助前列腺癌早期诊断:进展与展望

阅读:2

Abstract

Prostate cancer is one of the most common cancers affecting men worldwide. Owing to late diagnosis, the mortality rate associated with prostate cancer remains relatively high. Traditional diagnostic methods are, in most cases, unfriendly to patients or have diagnostic lag defects. Further diagnosis requires prostate biopsy. The most common biomarker is prostate-specific antigen, which is quantified as the content of the prostate health index to describe the risk of prostate cancer. Traditional biochemical analysis methods are costly, time-consuming, and lack specificity. They are also limited by the detection range, preventing high sensitivity. The exploration of novel biomarkers has identified several promising alternatives. The development of integrated nanomaterial technology provides a feasible potential method for the rapid, sensitive and non-invasive determination of these biological markers and assists in the optimisation of imaging diagnosis, which is expected to solve the current challenges in the diagnosis of prostate cancer. This paper reviews the advances in the diagnostic screening and imaging of prostate cancer using nanostructure-based biofunctional sensors, probes and contrast agents such as gold nanoparticles, upconversion nanoparticles, quantum dots, and magnetic nanoparticles. It also highlights the potential of emerging paradigms in nanoarchitectonics to definitive cancer diagnosis.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。